Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy

• Main Authors: Bova M (Author), Valerieva A (Author), Wu MA (Author), Senter R (Author), Perego F (Author)
• Format: Book
• Published: Dove Medical Press, 2019-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Maria Bova,1 Anna Valerieva,2 Maddalena Alessandra Wu,3 Riccardo Senter,4 Francesca Perego5 1Department of Translational Medical Sciences and Interdepartmental Center for Research in Basic and Clinical Immunology Sciences, University of Naples Federico II, Naples, Italy; 2Clinical Centre of Allergology, Medical University of Sofia, Sofia, Bulgaria; 3Department of Biomedical Science, University of Milan, Milan, Italy; 4Department of Medicine, University of Padova, Padova, Italy; 5Department of Cure Subacute, Istituti Clinici Scientifici Maugeri, IRCCS, Milan, ItalyCorrespondence: Francesca PeregoDepartment of Cure Subacute, Istituti Clinici Scientifici Maugeri, IRCCS, via Camaldoli 64, Milan 20138, ItalyTel [phone]Email [e-mail]: Despite the efficacy of the on-demand treatment for the control of acute attacks of Hereditary Angioedema due to C1-Inhibitor Deficiency (C1-INH-HAE), the number and severity of attacks and the impairment in the quality of life of the affected patients have led to the development of a new monoclonal antibody, lanadelumab, directly addressed to the blockage of bradykinin, the principal mediator of vasodilation during angioedema attacks. It is indicated for the prophylactic treatment, it is easy to administer, highly effective and with known limited side effects. The current review summarizes the development of the drug, its clinical background and its perspectives.Keywords: C1-inhibitor hereditary angioedema, long-term prophylaxis, lanadelumab, monoclonal antibody, rare disease

Item Description

1177-8881